Details of the Drug

General Information of Drug (ID: DM9JXB7)

Drug Name

Retapamulin

Synonyms

Altabax; Altargo; SB 275833; Altabax (Glaxo); Altabax (TN); Altargo (TN); Retapamulin (USAN/INN)

Indication

Disease Entry	ICD 11	Status	REF
Impetigo	1B72	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antibiotics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 2

Molecular Weight (mw)

517.799

Logarithm of the Partition Coefficient (xlogp)

6.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Metabolism: The drug is metabolized via the liver []

Chemical Identifiers

Formula: C30H47NO4S
IUPAC Name: [(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]sulfanyl]acetate
Canonical SMILES: C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4C[C@H]5CC[C@@H](C4)N5C)C
InChI: InChI=1S/C30H47NO4S/c1-7-28(4)16-24(35-25(33)17-36-22-14-20-8-9-21(15-22)31(20)6)29(5)18(2)10-12-30(19(3)27(28)34)13-11-23(32)26(29)30/h7,18-22,24,26-27,34H,1,8-17H2,2-6H3/t18-,19+,20-,21+,22?,24-,26+,27+,28-,29+,30+/m1/s1
InChIKey: STZYTFJPGGDRJD-FJJJPKKESA-N

Cross-matching ID

PubChem CID: 6918462
ChEBI ID: CHEBI:166679
CAS Number: 224452-66-8
DrugBank ID: DB01256
TTD ID: D03UQM

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial 50S ribosomal RNA (Bact 50S rRNA)	TTUWYEA	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Retapamulin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Posaconazole	DMUL5EW	Minor	Decreased metabolism of Retapamulin caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[3]
Dalfopristin	DM4LTKV	Minor	Decreased metabolism of Retapamulin caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[3]
Troleandomycin	DMUZNIG	Minor	Decreased metabolism of Retapamulin caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[3]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Retapamulin caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[4]
Lapatinib	DM3BH1Y	Minor	Decreased metabolism of Retapamulin caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[3]
Tucatinib	DMBESUA	Minor	Decreased metabolism of Retapamulin caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[3]
Osilodrostat	DMIJC9X	Minor	Decreased metabolism of Retapamulin caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[3]
MK-8228	DMOB58Q	Minor	Decreased metabolism of Retapamulin caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[3]
Stiripentol	DMMSDOY	Minor	Decreased metabolism of Retapamulin caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[3]
Fosamprenavir	DM4W9B3	Minor	Decreased metabolism of Retapamulin caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[3]
Cobicistat	DM6L4H2	Minor	Decreased metabolism of Retapamulin caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[3]
Darunavir	DMN3GCH	Minor	Decreased metabolism of Retapamulin caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[3]
Berotralstat	DMWA2DZ	Minor	Decreased metabolism of Retapamulin caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[3]
Ceritinib	DMB920Z	Minor	Decreased metabolism of Retapamulin caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[3]
Selpercatinib	DMZR15V	Minor	Decreased metabolism of Retapamulin caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[3]
Idelalisib	DM602WT	Minor	Decreased metabolism of Retapamulin caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[3]
IPI-145	DMWA24P	Minor	Decreased metabolism of Retapamulin caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[3]
Danazol	DML8KTN	Minor	Decreased metabolism of Retapamulin caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[3]
Fedratinib	DM4ZBK6	Minor	Decreased metabolism of Retapamulin caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[3]
Netupitant	DMEKAYI	Minor	Decreased metabolism of Retapamulin caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[3]
Entrectinib	DMMPTLH	Minor	Decreased metabolism of Retapamulin caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[3]
Rucaparib	DM9PVX8	Minor	Decreased metabolism of Retapamulin caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[3]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Retapamulin caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[5]
Lonafarnib	DMGM2Z6	Minor	Decreased metabolism of Retapamulin caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[3]
Voxelotor	DMCS6M5	Minor	Decreased metabolism of Retapamulin caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[3]
Larotrectinib	DM26CQR	Minor	Decreased metabolism of Retapamulin caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[3]
LEE011	DMMX75K	Minor	Decreased metabolism of Retapamulin caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[3]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Retapamulin caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[6]
-----------


⏷ Show the Full List of 28 DDI Information of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022055.
2	Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Antimicrob Agents Chemother. 2007 Sep;51(9):3385-7.
3	Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
4	Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA.
5	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
6	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.